All Stories

  1. Cardiovascular and skeletal safety of zoledronic acid in osteoporosis observational, matched cohort study using Danish and Swedish health registries
  2. Oral bisphosphonate use and all‐cause mortality in patients with moderate‐severe (grade 3B‐5D) chronic kidney disease: a population‐based cohort study
  3. Fractures in women with eating disorders—Incidence, predictive factors, and the impact of disease remission: Cohort study with background population controls
  4. Age at hip fracture and life expectancy in Denmark – Secular trends over two decades
  5. Proton pump inhibitors and fracture risk. The HUNT study, Norway
  6. Osteoporotic Fractures in Patients With Atrial Fibrillation Treated With Conventional Versus Direct Anticoagulants
  7. Increased risk of thyroid disease in Danish women with polycystic ovary syndrome: a cohort study
  8. The Latest Evidence from Vitamin D Intervention Trials for Skeletal and Non-skeletal Outcomes
  9. Tramadol prescribed use in general and chronic noncancer pain: a nationwide register-based cohort study of all patients above 16 years
  10. Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskele...
  11. Fracture risk following intermission of osteoporosis therapy
  12. Duration of over- and under-treatment of hypothyroidism is associated with increased cardiovascular risk
  13. Excess mortality following hip fracture in patients with diabetes according to age: a nationwide population-based cohort study of 154,047 hip fracture patients
  14. Lack of Transparency in the Meta-Analyses of Dietary and Urinary Sodium and Bone Mineral Density or Risk of Osteoporosis: A Letter to the Journal
  15. Long term time trends in use of medications associated with risk of developing osteoporosis: Nationwide data for Denmark from 1999 to 2016
  16. Pre-fracture medication use as a predictor of 30-day mortality in hip fracture patients: an analysis of 141,201 patients
  17. Duration of Hyperthyroidism and Lack of Sufficient Treatment Are Associated with Increased Cardiovascular Risk
  18. Osteoporosis and prostate cancer; a 24-month prospective observational study during androgen deprivation therapy
  19. Biochemical markers of inflammation are associated with increased mortality in hip fracture patients: the Bispebjerg Hip Fracture Biobank
  20. Osteoporosis; Prevention and Ca—Vitamin D Treatment
  21. Socioeconomic status in Danish women with polycystic ovary syndrome: A register-based cohort study
  22. Hip fracture rates and time trends in use of anti-osteoporosis medications in Denmark for the period 2005 to 2015: Missed opportunities in fracture prevention
  23. Does bisphosphonate treatment reduce the risk of future cancer?
  24. Side effects of drugs for osteoporosis and metastatic bone disease
  25. VITAMIN D supplementation for musculoskeletal Health outcomes in adults – THE END OF THE BEGINNING?
  26. Clinical improvement in a patient with monostotic melorheostosis after treatment with denosumab: a case report
  27. High calcium intake in men not women is associated with all-cause mortality risk: Melbourne Collaborative Cohort Study
  28. Atypical Femur Fractures: Review of Epidemiology, Relationship to Bisphosphonates, Prevention, and Clinical Management
  29. A New Fracture Risk Assessment Tool (FREM) Based on Public Health Registries
  30. Diagnosis and management of bone fragility in diabetes: an emerging challenge
  31. Persistence of Excess Mortality Following Individual Nonhip Fractures: A Relative Survival Analysis
  32. Social inequality and fractures—secular trends in the Danish population: a case-control study
  33. Anti-osteoporosis drug use: too little, too much, or just right? The HUNT study, Norway
  34. Over- and Under-Treatment of Hypothyroidism Is Associated with Excess Mortality: A Register-Based Cohort Study
  35. The Changing Role of Patient Education in Osteoporosis
  36. Cardiovascular disease in a nationwide population of Danish women with polycystic ovary syndrome
  37. Lactose avoidance and bone
  38. The emperor redressed: treating osteoporosis to prevent hip fractures in the oldest old
  39. Response to letter: Development and risk factors of type 2 diabetes in a nationwide population of women with polycystic ovary syndrome
  40. Evidence for the prevention of bone loss in elderly and old early non-metastatic breast cancer patients treated with aromatase inhibitors
  41. Danish, national cross-sectional observational study on the prevalence of prior major osteoporotic fractures in adults presenting with hip fracture—limitations and scope for fracture liaison services in prevention of hip fracture
  42. Bespoke or one size fits all—Vitamin D fortification, targeted supplementation in risk groups or individual measurement?
  43. The risk of osteoporosis in oral steroid treatment for nasal polyposis: a systematic review
  44. Development and Risk Factors of Type 2 Diabetes in a Nationwide Population of Women With Polycystic Ovary Syndrome
  45. Erratum to: Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting
  46. Excess of all-cause mortality after a fracture in type 2 diabetic patients: a population-based cohort study
  47. Validation of FRAX and the impact of self-reported falls among elderly in a general population: the HUNT study, Norway
  48. Surgically treated osteonecrosis and osteomyelitis of the jaw and oral cavity in patients highly adherent to alendronate treatment: a nationwide user-only cohort study including over 60,000 alendronate users
  49. Neonatal vitamin D status from archived dried blood spots and future risk of fractures in childhood: results from the D-tect study, a population-based case-cohort study
  50. Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting
  51. Excess Mortality in Treated and Untreated Hyperthyroidism Is Related to Cumulative Periods of Low Serum TSH
  52. The calcium and vitamin D controversy
  53. Women’s lived experiences of learning to live with osteoporosis: a longitudinal qualitative study
  54. Prenatal exposure to vitamin D from fortified margarine and risk of fractures in late childhood: period and cohort results from 222 000 subjects in the D-tect observational study
  55. Hyperkalemia is Associated with Increased 30-Day Mortality in Hip Fracture Patients
  56. International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates
  57. Abstracts
  58. The risk of osteoporosis in oral steroid treatment for nasal polyposis: a systematic review
  59. Cardiovascular disease in patients with osteogenesis imperfecta — a nationwide, register-based cohort study
  60. Diagnostic devices for osteoporosis in the general population: A systematic review
  61. Mechanisms of diabetes mellitus-induced bone fragility
  62. Recent hip fracture trends in Sweden and Denmark with age-period-cohort effects
  63. Maternal serum retinol and  -carotene concentrations and neonatal bone mineralization: results from the Southampton Womens Survey cohort
  64. Fracture Rates and Fracture Sites in Patients With Osteogenesis Imperfecta: A Nationwide Register-Based Cohort Study
  65. Reply to: systematic review and meta-analysis for the association of bone mineral density and osteoporosis/osteopenia with vascular calcification in women
  66. Epidemiology of Fractures in Diabetes
  67. Mortality and Causes of Death in Patients With Osteogenesis Imperfecta: A Register-Based Nationwide Cohort Study
  68. Proton pump inhibitors and osteoporosis
  69. Osteoporosis treatment: bisphosphonates reign to continue for a few more years, at least?
  70. Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study
  71. Low Levels of Hemoglobin at Admission Are Associated With Increased 30-Day Mortality in Patients With Hip Fracture
  72. Temporal trends in the use of antithrombotics at admission
  73. Real-Life and RCT Participants: Alendronate Users Versus FITs’ Trial Eligibility Criterion
  74. Risk of fracture in adults on renal replacement therapy: a Danish national cohort study
  75. World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2016): Non-sponsored Symposia Abstracts
  76. Patients With Atypical Femur Fractures Have the Same Mortality as the Background Population-Drug-Channeling Bias, Bisphosphonate Effects, and Public Health Implications
  77. The epidemiology of fractures in Denmark in 2011
  78. The Duration and Safety of Osteoporosis Treatment
  79. Incidence and Predictors of Multiple Fractures Despite High Adherence to Oral Bisphosphonates: A Binational Population-Based Cohort Study
  80. Abstracts
  81. Bisphosphonate drug holidays: we reap what we sow
  82. Fracture Risk Is Decreased in Women With Polycystic Ovary Syndrome: A Register-Based and Population-Based Cohort Study
  83. Risks and Benefits of Bisphosphonate Therapies
  84. Hyponatremia and hypernatremia are associated with increased 30-day mortality in hip fracture patients
  85. Is allopurinol use associated with an excess risk of osteoporotic fracture? A National Prescription Registry study
  86. Nutrient and food intakes in early life and risk of childhood fractures: a systematic review and meta-analysis
  87. Use of anti-osteoporotic drugs in central Norway after a forearm fracture
  88. Bone: Sequential osteoporosis treatment—the order of things
  89. Vitamin D and spontaneous abortion
  90. Life Expectancy in Patients Treated for Osteoporosis: Observational Cohort Study Using National Danish Prescription Data
  91. The Excess Risk of Major Osteoporotic Fractures in Hypothyroidism Is Driven by Cumulative Hyperthyroid as Opposed to Hypothyroid Time: An Observational Register-Based Time-Resolved Cohort Analysis
  92. A 24-Month Study Evaluating the Efficacy and Safety of Denosumab for the Treatment of Men With Low Bone Mineral Density: Results From the ADAMO Trial
  93. Morbidity and medicine prescriptions in a nationwide Danish population of patients diagnosed with polycystic ovary syndrome
  94. Denosumab: A novel antiresorptive drug for osteoporosis
  95. World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2015): Poster Abstracts
  96. Osteoporosis Conference 2014
  97. Oral Bisphosphonate Use and Total Knee/Hip Implant Survival: Validation of Results in an External Population-Based Cohort
  98. Duration of Thyroid Dysfunction Correlates with All-Cause Mortality. The OPENTHYRO Register Cohort
  99. Subsequent fracture rates in a nationwide population-based cohort study with a 10-year perspective
  100. A review of lifestyle, smoking and other modifiable risk factors for osteoporotic fractures
  101. Epidemiology of forearm fractures in adults in Denmark: national age- and gender-specific incidence rates, ratio of forearm to hip fractures, and extent of surgical fracture repair in inpatients and outpatients
  102. Low Serum Thyrotropin Level and Duration of Suppression as a Predictor of Major Osteoporotic Fractures-The OPENTHYRO Register Cohort
  103. Comment on Tadrous et al.: Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis
  104. Predictors of second fracture while on treatment with oral bisphosphonates: a multinational retrospective cohort study
  105. Osteoporosis and prostate cancer: a cross-sectional study of Danish men with prostate cancer before androgen deprivation therapy
  106. Status of drug development for the prevention and treatment of osteoporosis
  107. Women's experiences of their osteoporosis diagnosis at the time of diagnosis and 6 months later: A phenomenological hermeneutic study
  108. Response: Is heart failure a debatable end-point for bisphosphonate treatment in an older osteoporotic population?
  109. Proton pump inhibitor use and fracture risk — effect modification by histamine H1 receptor blockade. Observational case–control study using National Prescription Data
  110. Osteoporosis in the European Union: a compendium of country-specific reports
  111. Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research
  112. Eliminating the need for fasting with oral administration of bisphosphonates
  113. Comparison of different screening tools (FRAX®, OST, ORAI, OSIRIS, SCORE and age alone) to identify women with increased risk of fracture. A population-based prospective study
  114. Nationwide registry-based analysis of cardiovascular risk factors and adverse outcomes in patients treated with strontium ranelate
  115. Risk assessment tools to identify women with increased risk of osteoporotic fracture: Complexity or simplicity? A systematic review
  116. Safety issues with bisphosphonate therapy for osteoporosis
  117. Parity and tanned white skin as novel predictors of vitamin D status in early pregnancy: a population-based cohort study
  118. Heart failure in patients treated with bisphosphonates
  119. The bisphosphonates: risks and benefits of long term use
  120. The influence of early exposure to vitamin D for development of diseases later in life
  121. The role of vitamin D supplementation in patients with rheumatic diseases
  122. Periarticular and generalised bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trial
  123. Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs—an analysis using national health databases
  124. Findings of Danish study on risk of colon cancer in bisphosphonate users were misinterpreted
  125. Inflammatory eye reactions in patients treated with bisphosphonates and other osteoporosis medications: Cohort analysis using a national prescription database
  126. Anti-osteoporotic therapy in Denmark—predictors and demographics of poor refill compliance and poor persistence
  127. Time trends for alendronate prescription practices in women with chronic obstructive pulmonary disease and women exposed to systemic glucocorticoids
  128. Characteristics of patients who suffer major osteoporotic fractures despite adhering to alendronate treatment: a National Prescription registry study
  129. A Randomized, Placebo-Controlled Study of the Effects of Denosumab for the Treatment of Men with Low Bone Mineral Density
  130. Antidepressant medications and osteoporosis
  131. Central nervous system medications and falls risk in men aged 60-75 years: the Study on Male Osteoporosis and Aging (SOMA)
  132. Vitamin D with Calcium Reduces Mortality: Patient Level Pooled Analysis of 70,528 Patients from Eight Major Vitamin D Trials
  133. Bisphosphonates and colon cancer: reply
  134. Analysis of the association between bisphosphonate treatment survival in Danish hip fracture patients—a nationwide register-based open cohort study
  135. Bone geometry, density, and microarchitecture in the distal radius and tibia in adults with osteogenesis imperfecta type I assessed by high-resolution pQCT
  136. Are long-term bisphosphonate users a reality? Dose years for current bisphosphonate users assessed using the danish national prescription database
  137. Beyond a reasonable doubt? Bisphosphonates and atypical femur fractures
  138. Characteristics of patients who suffer major osteoporotic fractures despite adhering to bisphosphonate treatment: A national prescription register study
  139. Atypical femur fractures: Refining the clinical picture
  140. Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases
  141. Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate—Danish National Register Based Cohort Study
  142. Disentangling the Emerging Evidence around Atypical Fractures
  143. Esophageal and gastric cancer incidence and mortality in alendronate users
  144. Osteoporosis and vertebral fractures in men aged 60-74 years
  145. Season of Birth and the Risk of Hip Fracture in Danish Men and Women Aged 65+
  146. Older women who use bisphosphonate for longer than 5 years may have increased odds of a subtrochanteric or femoral shaft fracture, but absolute risk is low
  147. Screening: FRAX® in clinical practice
  148. Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the American Society for Bone and Mineral Research
  149. Safety of bisphosphonates
  150. Proton Pump Inhibitor Use and the Antifracture Efficacy of Alendronate
  151. Bone freezing and bisphosphonates
  152. Do calcium plus vitamin D supplements increase cardiovascular risk?
  153. Fracture risk assessed by Fracture Risk Assessment Tool (FRAX) compared with fracture risk derived from population fracture rates
  154. Risk factors for fracture in elderly men: a population-based prospective study
  155. Pattern of use of DXA scans in men: a cross-sectional, population-based study
  156. Cumulative Alendronate Dose and the Long-Term Absolute Risk of Subtrochanteric and Diaphyseal Femur Fractures: A Register-Based National Cohort Analysis
  157. Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research
  158. Vitamin D status and PTH in young men: a cross-sectional study on associations with bone mineral density, body composition and glucose metabolism
  159. Osteoporosis pharmacotherapy following bone densitometry: importance of patient beliefs and understanding of DXA results
  160. Prevalence of risk factors for fractures and use of DXA scanning in Danish women. A regional population-based study
  161. Bisphosphonate adverse effects, lessons from large databases
  162. Effects of COLIA1 polymorphisms and haplotypes on perimenopausal bone mass, postmenopausal bone loss and fracture risk
  163. Subtrochanteric and diaphyseal fractures in patients during long-term alendronate treatment: Expanded and extended national register based cohort study
  164. Adiponectin and Peak Bone Mass in Men: A Cross-Sectional, Population-Based Study
  165. Adverse Effects of Bisphosphonates
  166. Validation of a 5-year risk score of hip fracture in postmenopausal women. The Danish Nurse Cohort Study
  167. Excess mortality in men compared with women following a hip fracture. National analysis of comedications, comorbidity and survival
  168. Patient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US and Europe
  169. Subtrochanteric and Diaphyseal Femur Fractures in Patients Treated With Alendronate: A Register-Based National Cohort Study
  170. Prevention and treatment of osteoporosis in women: an update
  171. Declining incidence of hip fractures and the extent of use of anti-osteoporotic therapy in Denmark 1997–2006
  172. Excess mortality following hip fracture: a systematic epidemiological review
  173. Atrial fibrillation in fracture patients treated with oral bisphosphonates
  174. More on Reports of Esophageal Cancer with Oral Bisphosphonate Use
  175. No Association Between Hip Geometry and Four Common Polymorphisms Associated with Fracture: The Danish Osteoporosis Prevention Study
  176. Mapping the prescriptiome to fractures in men—a national analysis of prescription history and fracture risk
  177. Changes in bone mineral density (BMD) around the cemented Exeter stem: A prospective study in 18 women with 5 years follow-up
  178. Initiation of anti-osteoporotic therapy in patients with recent fractures: a nationwide analysis of prescription rates and persistence
  179. Polymorphisms in the Low-Density Lipoprotein Receptor-Related Protein 5 (LRP5) Gene Are Associated with Peak Bone Mass in Non-sedentary Men: Results from the Odense Androgen Study
  180. Fracture risk in Danish men with prostate cancer: a nationwide register study
  181. Erratum
  182. Disproportional geometry of the proximal femur in patients with Turner syndrome: a cross‐sectional study
  183. Single nucleotide polymorphisms in the P2X7 gene are associated to fracture risk and to effect of estrogen treatment
  184. Population-based reference values for bone mineral density in young men
  185. Comment on Schott et al.: Which screening strategy using BMD measurements would be most cost effective for hip fracture prevention in elderly women? A decision analysis based on a Markov model
  186. Estimates of fracture probability in Denmark: reply to Johansson et al
  187. Abnormal muscle and hematopoietic gene expression may be important for clinical morbidity in primary hyperparathyroidism
  188. Genetic variation in estrogen receptor, C-reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy
  189. Gene expression profiles give insight into the molecular pathology of bone in primary hyperparathyroidism
  190. Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: Results from the Danish Osteoporosis Prevention Study (DOPS)
  191. Ten-Year Absolute Risk of Osteoporotic Fractures According to BMD T Score at Menopause: The Danish Osteoporosis Prevention Study
  192. MTHFR c.677C>T polymorphism as an independent predictor of peak bone mass in Danish men—results from the Odense Androgen Study
  193. Ten-year prediction of osteoporosis from baseline bone mineral density: development of prognostic thresholds in healthy postmenopausal women. The Danish Osteoporosis Prevention Study
  194. Prevention and treatment of osteoporosis in women
  195. Utility of testing for monoclonal bands in serum of patients with suspected osteoporosis: retrospective, cross sectional study
  196. Circulating amounts of osteoprotegerin and RANK ligand: Genetic influence and relationship with BMD assessed in female twins
  197. Are effects of MTHFR (C677T) genotype on BMD confined to women with low folate and riboflavin intake? Analysis of food records from the Danish osteoporosis prevention study
  198. Geometry of the Proximal Femur in Relation to Age and Sex: a Cross-Sectional Study in Healthy Adult Danes
  199. Increased RANKL/OPG mRNA Ratio in Iliac Bone Biopsies From Women with Hip Fractures
  200. Performance of four clinical screening tools to select peri- and early postmenopausal women for dual X-ray absorptiometry
  201. Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-κb ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism
  202. Response rates to oestrogen treatment in perimenopausal women: 5-year data from The Danish Osteoporosis Prevention Study (DOPS)
  203. Dose-, IGF-I- and sex-dependent changes in lipid profile and body composition during GH replacement therapy in adult onset GH deficiency
  204. Two Single Nucleotide Polymorphisms in the CYP17 and COMT Genes—Relation to Bone Mass and Longitudinal Bone Changes in Postmenopausal Women with or without Hormone Replacement Therapy
  205. Osteoprotegerin Levels in Primary Hyperparathyroidism: Effect of Parathyroidectomy and Association with Bone Metabolism
  206. Standardization of BMD T-Scores in the First Five Years After the Menopause
  207. Effect of long-term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study
  208. A Common Methylenetetrahydrofolate Reductase (C677T) Polymorphism Is Associated With Low Bone Mineral Density and Increased Fracture Incidence After Menopause: Longitudinal Data From the Danish Osteoporosis Prevention Study
  209. Hormone Replacement Therapy Dissociates Fat Mass and Bone Mass, and Tends to Reduce Weight Gain in Early Postmenopausal Women: A Randomized Controlled 5-Year Clinical Trial of the Danish Osteoporosis Prevention Study
  210. Polymorphisms in the CYP19 and AR Genes?Relation to Bone Mass and Longitudinal Bone Changes in Postmenopausal Women With or Without Hormone Replacement Therapy: The Danish Osteoporosis Prevention Study
  211. Effects of the Natural and Artificial Menstrual Cycle on the Production of Osteoprotegerin and the Bone Resorptive Cytokines IL-1b and IL-6
  212. Association of a Common Allelic Polymorphism (C677T) in the Methylene Tetrahydrofolate Reductase Gene with a Reduced Risk of Osteoporotic Fractures. A Case Control Study in Danish Postmenopausal Women
  213. Evaluation of the optimum dose of growth hormone (GH) for restoring bone mass in adult-onset GH deficiency: results from two 12-month randomized studies
  214. Two Polymorphisms in the Vitamin D Receptor Gene-Association With Bone Mass and 5-Year Change in Bone Mass With or Without Hormone-Replacement Therapy in Postmenopausal Women: The Danish Osteoporosis Prevention Study
  215. Effect of long-term hormone replacement therapy on plasma homocysteine in postmenopausal women: A randomized controlled study
  216. Evaluation of methods for prediction of bone mineral density by clinical and biochemical variables in perimenopausal women
  217. Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women — results of the Danish Osteoporosis Prevention Study
  218. Cytokines and Bone Loss in a 5-Year Longitudinal Study-Hormone Replacement Therapy Suppresses Serum Soluble Interleukin-6 Receptor and Increases Interleukin-1-Receptor Antagonist: The Danish Osteoporosis Prevention Study
  219. Errata
  220. Correlations between insulin sensitivity and bone mineral density in non-diabetic men
  221. Cytokine RNA levels in transiliac bone biopsies from healthy early postmenopausal women
  222. Vitamin D Receptor Alleles Do Not Predict Bone Mineral Density or Bone Loss in Danish Perimenopausal Women
  223. Site of Osteodensitometry in Perimenopausal Women: Correlation and Limits of Agreement Between Anatomic Regions
  224. Cross calibration of QDR-2000 and QDR-1000 dual-energy X-ray densitometers for bone mineral and soft-tissue measurements
  225. Relevance of Ki-67 expression in the classification of non-Hodgkin's lymphomas: a morphometric and double-immunostaining study